Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intraocular pressure and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iricryn is a prostaglandin analog used to manage conditions that involve elevated intraocular pressure. - Open‑angle glaucoma: reduces intraocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. - Normal‑tension glaucoma: helps maintain target pressure when pressures are within normal range but optic nerve damage persists.

Iricryn may cause ocular and peri‑ocular reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild hyperemia of the conjunctiva. - Eyelash changes: increased length, thickness, or darkness. - Periocular skin darkening: hyperpigmentation of the eyelid skin. - Eye irritation: transient burning or stinging on instillation.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract requiring medical attention. - Macular edema: swelling of the central retina that can affect vision. - Iris pigmentation: permanent darkening of the iris color. - Severe allergic reaction: swelling, rash, or difficulty breathing. - Vision loss: sudden decrease in visual acuity needing urgent evaluation.

Before prescribing Iricryn, clinicians should consider patient‑specific factors and monitor for adverse events. - Monitor intraocular pressure: assess IOP reduction after initiation. - Assess ocular inflammation: avoid use in active uveitis. - Caution in patients with a history of iris or skin pigmentation changes. - Avoid concurrent use with other prostaglandin analog eye drops. - Discontinue if severe allergic reaction occurs. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Iricryn can interact with other ophthalmic or systemic agents, altering efficacy or safety.

Major Interactions (Avoid): - Concomitant prostaglandin analogs: additive IOP‑lowering effect may cause hypotony. - Systemic carbonic anhydrase inhibitors: increased risk of excessive IOP reduction.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may diminish prostaglandin activity. - Beta‑blocker eye drops: monitor IOP for additive pressure‑lowering. - Anticholinergic agents: possible reduced aqueous outflow, watch IOP trends.